Professional
Added to YB: 2024-12-09
Pitch date: 2024-12-07
IKNA [bullish]
Ikena Oncology, Inc.
-14.37%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
Market Cap
$69.0M
Pitch Price
$20.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.58
P/E
-2.24
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Ikena Oncology: Liquidation Discount or Turnaround Opportunity?
IKNA: Trading 25% below projected net cash. Strategic review since May, possible outcome soon. Two workforce reductions. Top 5 shareholders own 40%+. OrbiMed sold down to 7.3% post-review announcement. Likely no R&D beyond Phase 1. Potential liquidation play.
Read full article (1 min)